Medicare claims data were used to evaluate risk factors for glaucoma progression and surgical burden in patients with presumed mild disease. Continued monitoring is needed in some patient groups who had prior successful laser trabeculoplasty. Source: AAO
This week in the news, ophthalmologists report pandemic-related burnout and stress, a phase 3 trial of cenegermin for severe Sjögren-related dry eye disease is enrolling patients, and higher corneal nerve loss is seen with increased painful diabetic neuropathy. Source: AAO
Investigators compared the preferred practice of treating amblyopia with sequential treatment (glasses, then occlusion) with simultaneous treatment (glasses and occlusion together). Source: AAO
Investigators in Japan conducted a retrospective cohort analysis to identify risk factors for epiretinal membrane (ERM) formation following pars plana vitrectomy (PPV) for rhegmatogenous retinal detachment (RRD) repair. Source: AAO
This case series found that gonioscopy-assisted transluminal trabeculotomy (GATT) in eyes with a history of prior corneal transplant resulted in fewer complications than other surgical approaches. Source: AAO
This subanalysis of the FAST trial, which compared methotrexate and mycophenolate mofetil in noninfectious uveitis, evaluated time to corticosteroid-sparing control of inflammation. Source: AAO
Faricimab was approved by the FDA in January 2022 for the treatment of neovascular AMD and diabetic macular edema (DME). This approval was partially based on 2 phase 3 studies, which also showed the potential to extend the time between treatments. Source: AAO
This week in the news, disparities in ophthalmic care between North American Native and White populations remain, migraine sufferers have a high risk of neovascular AMD, and thinner RNFL and GCL thickness may be a biomarker for early cognitive decline. Source: AAO
Liposomal ozonized oil plus hypromellose is a potential new option beyond povidine iodine to reduce bacterial flora load and the potential risk for endophthalmitis in cataract surgery. Source: AAO
Patients with diabetic macular edema (DME) who stopped anti-VEGF treatment for several months recovered vision and anatomic outcomes when treatment was resumed. Source: AAO